Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US.

Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also benefit from empagliflozin.

Deuruxolitinib 8 mg BID was found to be the most effective oral JAK inhibitor for severe alopecia areata in a new meta-analysis.

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Combining ELR with CT-based measures predicts olfactory recovery in CRSwNP patients, highlighting eosinophils' role in disease severity and dysfunction.

Geni Tunstall, JD, discusses how pharmacy benefit manager reforms, Medicaid changes, and the MAHA initiative may impact managed care pharmacy operations.

Experts at AMCP Nexus 2025 highlighted how real-world data can improve CAR T-cell therapy access and outcomes.

The FDA announced draft guidance to remove clinical efficacy studies for biosimilars and also issued the position that all biosimilars in the US should be interchangeable.

Increasing respiratory syncytial virus (RSV) vaccination among older adults could prevent up to 1600 deaths and 20,000 hospitalizations over 5 years.

Leaders from The US Oncology Network and McKesson discuss how technology can enhance precision medicine and improve patient access to cutting-edge cancer treatments.

Premiums for coverage on the ACA marketplaces are set to jump by an average of 26% next year, even before the expiration of subsidies is factored in.

The antiretroviral (ART) regimen Biktarvy showed higher 1-year ART persistence and lower switch rates among people with HIV.

Innovative cancer therapies are transforming treatment landscapes, yet access challenges persist. Experts discuss strategies to enhance patient care and outcomes.

Cancer care evolves with innovative therapies and financial challenges, emphasizing the need for equitable access and sustainable models in treatment delivery.

Real-world evidence helps pharmaceutical companies and payers communicate more effectively.

Oncology experts discuss the rapid advancements in cancer diagnostics and treatments, emphasizing the need for equitable access and infrastructure improvements.

Metabolic intermediates were identified as active participants in fibrosis progression and potential targets for next-generation therapies.

Experts discuss strategies for equitable access to genomic testing and cutting-edge therapies for uninsured non-small cell lung cancer patients.

Real-world data suggest metabolic dysfunction-associated steatotic liver disease is also associated with higher all-cause mortality.

Previous research has evaluated PD-1/PD-L1 immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), but research in the setting of limited-stage disease is sparse.

Symptoms of dry eye improved when patients in Canada used reproxalap compared with a placebo dose.

A session explores how value-based oncology integrates pharmacy, precision medicine, and real-world evidence to enhance lung cancer care and patient outcomes.

Radiomic assessment has been used to distinguish multiple sclerosis from similar disorders, and it might also be useful in identifying MS stages and subtypes.

Experts discuss oncology's challenges, including treatment costs and clinician burnout, while exploring innovative solutions for equitable patient care.